Ataraxis AI is a pioneering precision medicine company dedicated to transforming cancer diagnostics through advanced artificial intelligence. Their flagship product, Ataraxis Breast, is the world's first AI-native prognostic and predictive platform for breast cancer, offering a 30% improvement in accuracy over traditional genomic assays. By analyzing multi-modal patient data, including standard pathology slides, Ataraxis Breast provides personalized predictions regarding cancer recurrence risk, enabling more informed treatment decisions. This innovative approach not only enhances diagnostic precision but also aims to reduce unnecessary treatments, thereby improving patient outcomes and quality of life.